Mark Messak, Ahmed Abdelmageed, Abdelrahman A Senbel, Youssef A Khattab, Youssef Mandour, Omar Shaker, Ahmed Hamed Rehan, Samir Oransa, Mohamed Nasr, Abdullah Emad Shabeeb, Ziyad Rezq, Fares Hossam, Moaz Elsayed Abouelmagd
{"title":"Efficacy and safety of GLP-1 agonists in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.","authors":"Mark Messak, Ahmed Abdelmageed, Abdelrahman A Senbel, Youssef A Khattab, Youssef Mandour, Omar Shaker, Ahmed Hamed Rehan, Samir Oransa, Mohamed Nasr, Abdullah Emad Shabeeb, Ziyad Rezq, Fares Hossam, Moaz Elsayed Abouelmagd","doi":"10.1007/s00210-025-03932-3","DOIUrl":null,"url":null,"abstract":"<p><p>Recent trends suggest exploring the repurposing of different drugs for Parkinson's disease patients (PD). One of these drugs is Glucagon-like peptide-1 (GLP-1), a medication used to treat type 2 diabetes mellitus. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of different forms of GLP-1 agonists on motor and non-motor functions of PD patients during ON-medication and OFF-medication states. A literature search was conducted through PubMed, Scopus, Web of Science, OVID, Cochrane Central, and Google Scholar using relevant keywords. Quality assessment was performed using the Risk of Bias-2 (RoB-2) domains. Statistical analysis included calculating the mean difference (MD) and the corresponding 95% confidence intervals (CIs) using Review Manager 5.4.1. Four randomized controlled trials (RCTs) testing three different forms of GLP-1 agonists with a total of 514 patients were included in the study. GLP-1 agonists significantly improved motor function during the OFF-medication state (MD = - 3.29, 95% CI [- 5.17 to - 1.42], P = 0.0006). It does not show improvement in quality of life assessed by PDQ-39 (MD = - 0.54, 95% CI [- 2.07 to 0.99], P = 0.49). None of the adverse effects stated in the RCTs were higher in the GLP-1 agonists group except for nausea (RR = 1.98, P = 0.0008), vomiting (RR = 6.65, P = 0.0008), constipation (RR = 1.45, P = 0.01), and weight loss (RR = 2.11, P = 0.03). This systematic review and meta-analysis provide evidence that GLP-1 agonists could improve the motor function of PD patients. However, safety is still of concern. Further high-quality studies with standardized protocols and larger sample sizes are needed to confirm our findings.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Naunyn-Schmiedeberg's archives of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00210-025-03932-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Recent trends suggest exploring the repurposing of different drugs for Parkinson's disease patients (PD). One of these drugs is Glucagon-like peptide-1 (GLP-1), a medication used to treat type 2 diabetes mellitus. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of different forms of GLP-1 agonists on motor and non-motor functions of PD patients during ON-medication and OFF-medication states. A literature search was conducted through PubMed, Scopus, Web of Science, OVID, Cochrane Central, and Google Scholar using relevant keywords. Quality assessment was performed using the Risk of Bias-2 (RoB-2) domains. Statistical analysis included calculating the mean difference (MD) and the corresponding 95% confidence intervals (CIs) using Review Manager 5.4.1. Four randomized controlled trials (RCTs) testing three different forms of GLP-1 agonists with a total of 514 patients were included in the study. GLP-1 agonists significantly improved motor function during the OFF-medication state (MD = - 3.29, 95% CI [- 5.17 to - 1.42], P = 0.0006). It does not show improvement in quality of life assessed by PDQ-39 (MD = - 0.54, 95% CI [- 2.07 to 0.99], P = 0.49). None of the adverse effects stated in the RCTs were higher in the GLP-1 agonists group except for nausea (RR = 1.98, P = 0.0008), vomiting (RR = 6.65, P = 0.0008), constipation (RR = 1.45, P = 0.01), and weight loss (RR = 2.11, P = 0.03). This systematic review and meta-analysis provide evidence that GLP-1 agonists could improve the motor function of PD patients. However, safety is still of concern. Further high-quality studies with standardized protocols and larger sample sizes are needed to confirm our findings.
期刊介绍：
Naunyn-Schmiedeberg''s Archives of Pharmacology was founded in 1873 by B. Naunyn, O. Schmiedeberg and E. Klebs as Archiv für experimentelle Pathologie und Pharmakologie, is the offical journal of the German Society of Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, DGPT) and the Sphingolipid Club. The journal publishes invited reviews, original articles, short communications and meeting reports and appears monthly. Naunyn-Schmiedeberg''s Archives of Pharmacology welcomes manuscripts for consideration of publication that report new and significant information on drug action and toxicity of chemical compounds. Thus, its scope covers all fields of experimental and clinical pharmacology as well as toxicology and includes studies in the fields of neuropharmacology and cardiovascular pharmacology as well as those describing drug actions at the cellular, biochemical and molecular levels. Moreover, submission of clinical trials with healthy volunteers or patients is encouraged. Short communications provide a means for rapid publication of significant findings of current interest that represent a conceptual advance in the field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
